Topical mast cell stabiliser
Lodoxamide
Brand names: Alomide
Adult dose
Dose: 1–2 drops QDS
Route: Topical (ophthalmic)
Frequency: QDS
Clinical pearls
- Allergic conjunctivitis prophylaxis (regular use); not for acute relief
Contraindications
- Hypersensitivity
- Soft contact lenses (during use)
Side effects
- Transient stinging
- Blurred vision
Reference: BNF; https://bnf.nice.org.uk/drugs/lodoxamide/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- C-Peptide to Glucose Ratio · Diabetes Classification
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- HCT-CI — Haematopoietic Cell Transplant Comorbidity Index · Risk Stratification
- MSKCC/Motzer Score for Metastatic RCC · Cancer Prognosis
Pathways
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme